Fig. 4
From: The prognostic impact of macroscopic serosal change on resectable advanced gastric cancer
The 5-year survival rate in pStageIB–IIIC according to MSC positivity. A and B The 5-year survival rates were similar in patients with MSC (+) than MSC (−) tumors of pStageIB and IIA. C-F The 5-year survival rates were lower in patients with MSC (+) than MSC (−) tumors of pStageIIB (76.0% vs. 88.4%, P = 0.005), pStageIIIA (63.4% vs. 75.6%, P = 0.019), pStageIIIB (41.7% vs. 69.2%, P = 0.029) and pStageIIIC (27.6% vs. 50.0%, P = 0.062)